Department of Orthopaedics, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China.
Department of Orthopaedics, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China.
Biochem Biophys Res Commun. 2018 May 23;499(4):913-919. doi: 10.1016/j.bbrc.2018.04.019. Epub 2018 Apr 9.
Long non-coding RNA (LncRNA) dysregulation is associated with human osteosarcoma (OS) cell progression. Recent studies have characterized a novel but ultra-conserved LncRNA THOR ("Lnc-THOR") as a cancer-specific LncRNA, mediating cell growth. In the current study, we show that Lnc-THOR is expressed in established and primary human OS cells. It is also detected in human OS tissues, but not in the surrounding normal bone tissues. siRNA-induced knockdown or CRSIPR/Cas9-mediated knockout Lnc-THOR significantly inhibited human OS cell survival and proliferation. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) target mRNAs, including IGF2, GLI1 and CD44, were downregulated in Lnc-THOR-silenced OS cells as well. Conversely, forced over-expression of Lnc-THOR enhanced IGF2BP1 target mRNA expression, promoting OS cell survival and proliferation. In vivo, xenograft tumors of Lnc-THOR-knockout U2OS cells grew significantly slower than the control U2OS tumors. Together, these results show that Lnc-THOR expression is essential for human OS cell growth. Lnc-THOR could be a novel therapeutic target and/or diagnosis marker for human OS.
长链非编码 RNA(LncRNA)失调与人类骨肉瘤(OS)细胞的进展有关。最近的研究表明,一种新型但超保守的 LncRNA THOR(“Lnc-THOR”)作为一种癌特异性 LncRNA,介导细胞生长。在本研究中,我们表明 Lnc-THOR 在已建立和原代人骨肉瘤细胞中表达。它也存在于人类骨肉瘤组织中,但不存在于周围正常骨组织中。siRNA 诱导的敲低或 CRSIPR/Cas9 介导的 Lnc-THOR 敲除显著抑制了人骨肉瘤细胞的存活和增殖。Lnc-THOR 沉默的 OS 细胞中胰岛素样生长因子 2 mRNA 结合蛋白 1(IGF2BP1)靶 mRNA,包括 IGF2、GLI1 和 CD44,也下调。相反,强制过表达 Lnc-THOR 增强了 IGF2BP1 靶 mRNA 的表达,促进了 OS 细胞的存活和增殖。在体内,Lnc-THOR 敲除 U2OS 细胞的异种移植肿瘤的生长速度明显慢于对照 U2OS 肿瘤。总之,这些结果表明 Lnc-THOR 的表达对于人骨肉瘤细胞的生长是必不可少的。Lnc-THOR 可能是人类骨肉瘤的一种新的治疗靶点和/或诊断标志物。